Influvac

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) and Influenza A/Vic, the active ingredients in Influvac, are a vaccine presented as a vaccine for intramuscular/subcutaneous use. It stimulates immunity to prevent influenza infection in children and adults.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Influvac is indicated for active immunization against influenza viruses, targeting the seasonal flu disease family.

Seasonal influenza (A and B strains): reduces the risk of laboratory‑confirmed influenza infection. High‑risk groups (elderly, chronic respiratory or cardiac disease): lowers incidence of severe flu complications. Community outbreaks: contributes to herd immunity by decreasing overall virus circulation.

Common and rare adverse reactions may occur after administration of Influvac.

Common Side Effects: - Injection site pain: mild to moderate soreness at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise within 24 hours. - Headache or muscle aches: mild systemic symptoms.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder potentially triggered post‑vaccination. - Seizures: infrequent occurrence, especially in children with pre‑existing conditions.

Before administering Influvac, consider the following precautions.

Allergy assessment: avoid if known hypersensitivity to any vaccine component. Pregnancy: consult a healthcare provider to weigh benefits and risks. Immunocompromised patients: vaccine may be less effective; evaluate individual benefit. Fever or acute illness: postpone vaccination until the condition resolves. Concurrent vaccines: separate administration by at least 4 weeks unless otherwise advised. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Influvac may interact with other therapies; monitor as indicated.

Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration to prevent interference with immune response. - Immunoglobulin therapy: may diminish vaccine efficacy if given concurrently.

Moderate Interactions (Monitor Closely): - Antipyretic medications: may mask post‑vaccination fever, monitor temperature. - Immunosuppressive drugs: reduced antibody response, assess benefit‑risk. - Blood products or plasma: can interfere with immune activation, consider timing.